Drug
Jnj 18038683
Jnj 18038683: highest development phase Phase 2, developed by Johnson & Johnson. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| JNJ-18038683 NCT00566202 | Phase 2 | Major Depressive Disorder |
Latest
No recent events.
Follow Jnj 18038683 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.